Neurotrack, a Redwood City-based startup developing cognitive tests that can detect impairments in the hippocampus, the first structure in the brain to be affected by Alzheimer’s, today announced that it’s raised $21 million in series C financing led by by Khosla Ventures, with participation from strategic investors Sozo Ventures, Japanese insurance providers Dai-ichi Life and Sompo Holdings, Rethink Impact, and AME Cloud Partners. Previous backers include Johnson & Johnson and the Georgia Research Alliance (GRA)
The fresh capital brings Neurotrack’s total funding to date to $50 million, which includes over $7 million in grants from the National Institutes of Health. The company says the investments will be used to drive adoption of its memory health program, advance its mission of changing how people manage their cognitive health, and continue development in global markets.
Former White House and United Nations health program consultant and CEO Elli Kaplan’s life’s work is engineering early detection tools for mild cognitive impairment and related disorders. She cites the sobering statistics: Alzheimer’s affects more than 50 million people around the world (a number that’s expected to double every 20 years and reach 130 million by 2050), and there are nearly 10 million new cases of dementia
Read the rest of this post here